Integra LifeSciences Holdings Co. (NASDAQ:IART - Get Free Report)'s stock price crossed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $22.06 and traded as high as $26.28. Integra LifeSciences shares last traded at $25.22, with a volume of 773,625 shares trading hands.
Wall Street Analyst Weigh In
A number of analysts recently commented on IART shares. Citigroup raised their price target on Integra LifeSciences from $16.00 to $22.00 and gave the stock a "sell" rating in a research note on Tuesday, November 5th. Truist Financial dropped their price target on shares of Integra LifeSciences from $26.00 to $21.00 and set a "hold" rating on the stock in a research note on Monday, October 14th. Finally, Morgan Stanley assumed coverage on Integra LifeSciences in a research report on Monday, December 2nd. They issued an "underweight" rating and a $20.00 target price for the company. Three equities research analysts have rated the stock with a sell rating, five have given a hold rating and one has assigned a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus target price of $23.00.
View Our Latest Research Report on Integra LifeSciences
Integra LifeSciences Price Performance
The stock has a market capitalization of $1.98 billion, a price-to-earnings ratio of -285.30, a price-to-earnings-growth ratio of 0.87 and a beta of 1.17. The company's 50 day moving average is $23.85 and its 200 day moving average is $21.84. The company has a current ratio of 1.20, a quick ratio of 0.73 and a debt-to-equity ratio of 0.79.
Insider Buying and Selling
In other Integra LifeSciences news, EVP Michael J. Mcbreen sold 1,700 shares of the business's stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $24.16, for a total value of $41,072.00. Following the transaction, the executive vice president now directly owns 56,182 shares of the company's stock, valued at approximately $1,357,357.12. The trade was a 2.94 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 3.10% of the stock is owned by company insiders.
Institutional Trading of Integra LifeSciences
Hedge funds and other institutional investors have recently made changes to their positions in the company. Handelsbanken Fonder AB grew its position in shares of Integra LifeSciences by 22.9% in the third quarter. Handelsbanken Fonder AB now owns 23,602 shares of the life sciences company's stock valued at $429,000 after purchasing an additional 4,400 shares during the last quarter. Inspire Investing LLC lifted its position in shares of Integra LifeSciences by 88.8% in the third quarter. Inspire Investing LLC now owns 22,788 shares of the life sciences company's stock valued at $414,000 after acquiring an additional 10,715 shares in the last quarter. Exchange Traded Concepts LLC increased its position in Integra LifeSciences by 6.5% during the 3rd quarter. Exchange Traded Concepts LLC now owns 33,403 shares of the life sciences company's stock worth $607,000 after purchasing an additional 2,036 shares in the last quarter. Northwest Investment Counselors LLC acquired a new position in Integra LifeSciences in the 3rd quarter valued at about $73,000. Finally, Tandem Capital Management Corp ADV lifted its holdings in Integra LifeSciences by 43.4% in the 3rd quarter. Tandem Capital Management Corp ADV now owns 38,851 shares of the life sciences company's stock valued at $706,000 after purchasing an additional 11,765 shares in the last quarter. Hedge funds and other institutional investors own 84.78% of the company's stock.
Integra LifeSciences Company Profile
(
Get Free Report)
Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.
Featured Articles
Before you consider Integra LifeSciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Integra LifeSciences wasn't on the list.
While Integra LifeSciences currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
